Novocure

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novocure reports robust Q4 performance and eyes market expansion

Novocure's Q4 2022 performance showcased strong revenue growth, positive clinical outcomes, and ongoing investments in research and development.
Despite facing challenges in achieving positive adjusted EBITDA and addressing analyst inquiries, the company's strengths in innovation and partnerships position it for future success.
Opportunities in driving adoption of TTFields therapy, expanding into new indications, and leveraging partnerships underscore Novocure's growth potential in the oncology market.
With a focus on strategic planning and execution, Novocure aims to continue its trajectory of success, supported by a solid financial foundation and commitment to innovation.

NovoCure excels in Q1 with strong revenue and trial outcomes

NovoCure's Q1 2023 call highlighted strong financial performance, successful trial outcomes, and strategic plans for growth and innovation, while also acknowledging challenges in market expansion and patient growth.

Novocure reports robust Q2 earnings, advances innovative cancer therapies

Novocure's Q2 2023 performance reflects strong revenue growth and a focus on advancing innovative cancer therapies, particularly highlighted by the successful LUNAR trial results.
While facing challenges in regulatory processes and market expansion, Novocure's strategic strengths lie in its leadership in developing novel treatments and commitment to clinical advancement.
The upcoming Phase III trials and strategic initiatives present opportunities for Novocure to solidify its position as a key player in the oncology space and drive future growth.

NovoCure reports robust Q3 earnings, eyes global expansion and clinical milestones

NovoCure's Q3 performance reflects strong revenue growth and progress in clinical trials, particularly in lung cancer and GBM. While facing challenges related to denied payments and upcoming trials, the company remains resilient with exciting opportunities for global expansion and continued success in the oncology market.

NovoCure reports robust Q4 earnings, eyes growth in cancer therapies

NovoCure's Q4 2023 performance reflects strong financial results, progress in clinical trials, and a focus on extending survival in aggressive cancers through innovative therapies.
The company's strengths lie in its leadership in cancer treatment innovation, solid financial position, and commitment to disciplined growth strategies.
Challenges include regulatory approvals, managing cash burn, and maintaining cost efficiency, while opportunities abound in expanding product portfolio and advancing clinical trials for improved patient outcomes.

NovoCure excels in Q1 with record patient adoption and revenue growth

NovoCure's Q1 2024 performance reflects strong patient adoption, revenue growth, and strategic financial decisions to support future expansion and innovation.
While facing challenges related to regulatory processes and market dynamics, NovoCure's focus on clinical advancements and financial stability positions it well for long-term success.
The company's strengths in innovative therapies, positive trial outcomes, and financial resilience offer a solid foundation for seizing growth opportunities and overcoming potential obstacles.

NovoCure reports robust Q2 performance and outlines growth strategies

NovoCure's Q2 performance reflects strong financial results, patient growth, and progress in clinical programs, positioning the company for continued success.
Clear objectives set for 2024 and confidence expressed by executives indicate a strategic focus on growth and innovation in cancer therapy.
While facing challenges in regulatory processes and market competition, NovoCure has opportunities to leverage its strengths in commercialization and clinical development for future expansion.

Novocure reports robust Q3 earnings, eyes growth in cancer treatments

Novocure's Q3 performance reflects solid financial growth and patient adoption, supported by a strong focus on innovative cancer treatments and clinical advancements.
While leadership transitions and reimbursement challenges exist, the company's strategic initiatives and pipeline progress position them well for future success and market expansion.
Overall, Novocure's commitment to extending survival in aggressive cancers, coupled with operational improvements and market opportunities, underpin a positive outlook for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NovoCure Limited (NASDAQ:NVCR ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Ingrid Goldberg - IR Bill Doyle - Chairman Ashley Cordova - CFO Asaf Danziger - CEO Frank Leonard - EVP and President of NovoCure Oncology Nicolas Leupin - Chief Medical Officer Conference Call Participants Jason Bednar - Piper Sandler Jonathan Chang - Leerink Partners Emily Bodnar - H.C. Wainwright Jessica Fye - JPMorgan Operator Good day, and thank you for standing by.

NovoCure Limited (NVCR) Q3 2024 Earnings Conference Call Transcript

NovoCure (NVCR) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.46 per share a year ago.

NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Appoints Christoph Brackmann as Chief Financial Officer.

Novocure Appoints Christoph Brackmann as Chief Financial Officer

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Reports Third Quarter 2024 Financial Results.

Novocure Reports Third Quarter 2024 Financial Results

On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment which resulted in positive price action. The lung cancer market will significanly increase Novocure's scale, on top of a strong core business that has beat growth expectations. With downside risks limited to execution or FDA recall, and a price target of $35.10, I raise my rating from buy to strong buy.

NovoCure: There Is Still More Upside

On Tuesday, the FDA approved NovoCure's NVCR Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen.

FDA Approves NovoCure's Portable Device Producing Tumor-Treating Electric Fields For Previously Treated Lung Cancer Patients

NovoCure (NVCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

NovoCure (NVCR) Surges 10.7%: Is This an Indication of Further Gains?

Novocure stock rocketed late Tuesday after the FDA signed off on its treatment for patients with metastatic lung cancer.

Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 inhibitors or docetaxel, for the treatment of adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen. “Novocure is committed to extending survival in some of the most aggressive and difficult to treat cancers. The approval of Optune Lua brings a.

FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open.

Novocure to Report Third Quarter 2024 Financial Results

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to Present Real-World Data at ESMO 2024.

Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy

The commercial-stage biotech's leader is stepping down. This change is effective on Jan. 1, 2025.

Why NovoCure Stock Dived by 13% This Week

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Announces Planned CEO Transition.

Novocure Announces Planned CEO Transition

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to Participate in 2024 Wells Fargo Healthcare Conference.

Novocure to Participate in 2024 Wells Fargo Healthcare Conference

The average of price targets set by Wall Street analysts indicates a potential upside of 36% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think NovoCure (NVCR) Could Surge 35.96%: Read This Before Placing a Bet

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure today announced its participation in the upcoming International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer.

Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer

Carvana

Kinross Gold

Kiniksa Pharmaceuticals Ltd

Micron Technology

NVCR, KGC, CVNA, KNSA and MU have been added to the Zacks Rank #1 (Strong Buy) List on August 1, 2024.

New Strong Buy Stocks for August 1st

The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Believe NovoCure (NVCR) Could Rally 26.39%: Here's is How to Trade

Today, we take a look at NovoCure Limited, which develops and manufactures tumor treating fields devices for solid tumor cancers. The company has beat expectations for both its first and second quarter results in 2024 and is pushing to garner approval for additional indications. An analysis of NovoCure following its better than expected performance Q2 results Thursday follows in the paragraphs below.

NovoCure Limited: A Post Q2 Analysis

Its loss of $0.31 per share was smaller than the expected loss of $0.40 per share. Total net revenues of $150.4 million surpassed Wall Street's estimate of $135.8 million by 10.7%.

NovoCure's Q2 Revenue Soars by 10.7%

NovoCure Limited [NVCR] Q2 2024 Earnings Conference Call July 25, 2024 8:00 AM ET Company Participants Bill Doyle - Executive Chairman Asaf Danziger - CEO Ashley Cordova - CFO Frank Leonard - EVP and President of NovoCure Oncology Nicolas Leupin - Chief Medical Officer Ingrid Goldberg - Investor Relations Conference Call Participants Jonathan Chang - Leerink Partners Jason Bednar - Piper Sandler Larry Biegelsen - Wells Fargo Jessica Fye - J.P. Morgan Vijay Kumar - Evercore ISI Emily Bodnar - H.C.

NovoCure Limited (NVCR) Q2 2024 Earnings Call Transcript

NovoCure (NVCR) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.54 per share a year ago.

NovoCure (NVCR) Reports Q2 Loss, Tops Revenue Estimates

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2024.

Novocure Reports Second Quarter 2024 Financial Results

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company's financial results for the three and six months ended June 30, 2024, at 8:00 a.m. EDT on Thursday, July 25, 2024. To access the conference call by phone, use the following conference call registration link.

Novocure to Report Second Quarter 2024 Financial Results

ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ: NVCR) today announced the presentation of clinical data from the phase 3 METIS trial, which investigated the use of Tumor Treating Fields (TTFields) therapy in the treatment of brain metastases from non-small cell lung cancer (NSCLC). These data will be presented at the ongoing 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The METIS trial enrolled 298 adult patients with 1-10 brain metastases from NSCLC, who we.

METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival

News for Novocure Stock (NVCR)